Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These f...

Full description

Bibliographic Details
Main Authors: Oliver Kepp, Laurence Zitvogel, Guido Kroemer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-10-01
Series:OncoImmunology
Subjects:
anthracyclins
immunogenic cell death
pd-1
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1637188
Description
Summary:In preclinical in vivo models of cancer, the induction of immunogenic cell death (ICD) sensitizes to subsequent immunotherapy. Several clinical trials now confirm that pretreatment with ICD-inducing anthracyclines sensitizes to immune checkpoint blockade targeting PD-1 and PD-L1 interaction. These findings support the translational utility of the concept of ICD.
ISSN:2162-402X

Similar Items